HomeNDC LookupIngredientsTriamcinolone Acetonide › 68071-2736-03
Triamcinolone Acetonide 1 mg/g Cream — NDC 68071-2736-03 package photo

Triamcinolone Acetonide 1 mg/g Cream

by NuCare Pharmaceuticals,Inc. · 1 TUBE in 1 CARTON (68071-2736-3) / 30 g in 1 TUBE
NDC 68071-2736-03
🏷️ FDA NDC (as labeled) 68071-2736-3 billing pads the package segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 68071-2736-3
Product NDC 68071-2736
11-digit billing NDC 68071273603
RxCUI 1014314
UNII F446C597KA
UPC 0368071273632
Application # ANDA040039
SPL Set ID dff0403f-1c0c-3333-e053-2a95a90a4c09
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1997-11-26
Route TOPICAL
Dosage form CREAM
Substance TRIAMCINOLONE ACETONIDE
TE code (Orange Book) AT · RLD · RS
Why two NDCs? The FDA registers this code as 68071-2736-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 68071-2736-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerNuCare Pharmaceuticals,Inc.
Application holderTARO PHARMACEUTICAL INDUSTRIES LTD
FDA applicationANDA040039 (ANDA)
Labeler code68071
First marketedNov 1997
Product typeHuman Prescription Drug
Portfolio1,015 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

📗 Our plain-language guide HelloPharmacist
  • Yes, intra-articular triamcinolone is specifically approved to give short-term relief for knee arthritis, gout flares, bursitis, and similar joint conditions. The extended-release...
  • I'm getting a triamcinolone injection in my knee. Will it actually help, and how long does it last?
  • That's a really important thing to flag with your doctor before your injection or prescription. Triamcinolone can raise blood sugar — even in people whose diabetes is well-controll...
  • I have diabetes. Should I be worried about using triamcinolone?
📖 Read our full Triamcinolone guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII D072FFP9GU
    Cetyl esters wax is a waxy substance made from natural or synthetic fatty acids. It's used as a binder, hardening agent, and coating material to give tablets and capsules their structure and texture.
  • UNII 230OU9XXE4
    A waxy substance made from glycerin and stearic acid that acts as an emulsifier to blend oily and watery ingredients together. It also helps thicken and stabilize the medicine's texture.
  • UNII 8CRQ2TH63M
    Isopropyl palmitate is an oily liquid derived from palm oil. It acts as an emollient and lubricant in medicines, helping soften the skin or improve how the product spreads and flows.
  • UNII CAL22UVI4M
    A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.1230 $3.69 / 30 g
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide 1 mg/g 45802-0064-05 Padagis 454 g $0.028 AT Availability likely
Triamcinolone Acetonide 1 mg/g 45802-0055-05 Padagis 454 g $0.035 AT Availability likely
triamcinolone acetonide 1 mg/g 00168-0004-15 E. 1 tube $0.100 AT Availability likely
Triamcinolone Acetonide 1 mg/g 00713-0225-15 Cosette 1 tube $0.100 AT Discontinued
Triamcinolone Acetonide 1 mg/g 16714-0986-01 NorthStar 1 tube $0.100 AT Availability likely
Triamcinolone Acetonide 1 mg/g 21922-0062-04 Encube 1 tube $0.100 AT Availability likely
Triamcinolone Acetonide 1 mg/g 33342-0329-15 Macleods 1 tube $0.100 AT Availability likely
Triamcinolone Acetonide 1 mg/g 51672-1282-01 Sun 1 tube $0.100 AT Availability likely
Triamcinolone Acetonide 1 mg/g 67877-0251-15 Ascend 15 g $0.100 AT Availability likely
Triamcinolone Acetonide 1 mg/g 71656-0042-15 Saptalis 1 tube $0.100 AT Availability likely
Triamcinolone acetonide 1 mg/g 33342-0333-15 Macleods 1 tube $0.119 AT Availability likely
Triamcinolone Acetonide 1 mg/g 51672-1284-01 Sun 1 tube $0.119 AT Availability likely
Triamcinolone Acetonide 1 mg/g 00713-0228-15 Cosette 1 tube $0.119 AT Availability likely
Triamcinolone acetonide 1 mg/g 16714-0276-01 NorthStar 1 tube $0.119 AT Availability likely
Triamcinolone Acetonide 1 mg/g 21922-0063-04 Encube 1 tube $0.119 AT Availability likely
Triamcinolone Acetonide 1 mg/g 00168-0006-15 E. 15 g $0.119 AT Availability likely
Triamcinolone Acetonide 1 mg/g 64980-0320-05 Rising 1 tube $2.686 AT Availability likely
Triderm 1 mg/g 00316-0170-01 Crown 1 tube AT FDA listed
Triamcinolone acetonide 1 mg/g 50090-0162-00 A-S 80 g AT FDA listed
Triamcinolone acetonide 1 mg/g 50090-0228-00 A-S 15 g AT FDA listed
Triamcinolone acetonide 1 mg/g 50090-2106-00 A-S 30000 mg AT FDA listed
Triamcinolone Acetonide 1 mg/g 50090-6547-00 A-S 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 50090-6566-00 A-S 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 52817-0811-15 TruPharma, 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 61919-0234-30 Direct_Rx 30 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 61919-0650-15 DIRECTRX 15 g AT FDA listed
Triamcinolone acetonide 1 mg/g 63187-0025-15 Proficient 15 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 63187-0053-15 Proficient 15 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 63187-0870-15 Proficient 1 tube FDA listed
Triamcinolone acetonide 1 mg/g 63629-8778-01 Bryant 15 g AT FDA listed
Triamcinolone acetonide 1 mg/g 63629-8779-01 Bryant 30 g AT FDA listed
Triamcinolone acetonide 1 mg/g 63629-8780-01 Bryant 80 g AT FDA listed
Triamcinolone acetonide 1 mg/g 63629-8781-01 Bryant 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 63629-9573-01 Bryant 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 63629-9574-01 Bryant 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 66267-0933-80 NuCare 80 g FDA listed
Triamcinolone Acetonide 1 mg/gthis 68071-2736-03 NuCare 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-3666-03 NuCare 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-3852-08 NuCare 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-3982-05 NuCare 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-4383-05 NuCare 15 g FDA listed
triamcinolone acetonide 1 mg/g 68071-4391-03 NuCare 30 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-4945-05 NuCare 15 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 68462-0131-17 Glenmark 1 tube FDA listed
Triamcinolone Acetonide 1 mg/g 68788-7797-01 Preferred 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68788-8350-01 Preferred 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68788-8356-00 Preferred 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68788-8753-01 Preferred 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 70518-1524-00 REMEDYREPACK 15 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 70518-2285-00 REMEDYREPACK 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 70518-2403-00 REMEDYREPACK 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 70518-2963-00 REMEDYREPACK 1 tube AT Discontinued
Triamcinolone Acetonide 1 mg/g 70518-4527-00 REMEDYREPACK 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 71205-0627-15 Proficient 1 tube AT FDA listed
Triamcinolone acetonide 1 mg/g 71335-2211-01 Bryant 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 71335-2712-01 Bryant 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 71335-2713-01 Bryant 80 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72162-1386-04 Bryant 1 tube AT FDA listed
Triamcinolone acetonide 1 mg/g 72162-1832-03 Bryant 30 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72189-0039-80 Direct_Rx 80 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72189-0277-15 Direct_Rx 15 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72189-0330-80 Direct 80 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72189-0571-80 Direct_rx 80 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72189-0670-30 Direct_rx 30 g AT FDA listed
Dermavyx 72835-0777-02 V2 1 kit FDA listed
Triamcinolone Acetonide 1 mg/g 76420-0203-15 Asclemed 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 76420-0348-00 Asclemed 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 82804-0071-30 Proficient 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 82804-0145-30 Proficient 1 tube AT FDA listed
Triadermex 84460-0100-08 Florrax 1 kit FDA listed
Triamcinolone Acetonide 1 mg/g 50090-2244-00 A-S 1 tube AT FDA listed
Triamcinolone acetonide 1 mg/g 50090-6978-00 A-S 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68462-0797-17 Glenmark 1 tube FDA listed
Triamcinolone Acetonide 1 mg/g 71205-0108-15 Proficient 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-4286-05 NuCare 15 g FDA listed
Triamcinolone Acetonide 1 mg/g 50090-3508-00 A-S 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68071-1872-08 NuCare 80 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 70518-3689-00 REMEDYREPACK 1 tube AT FDA listed
Kourzeq 1 mg/g 82682-0001-05 MidAmerica 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 76420-0361-00 Asclemed 454 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 82804-0079-30 Proficient 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 50090-4761-00 A-S 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 50090-7679-00 A-S 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 61919-0619-15 DIRECTRX 15 g AT FDA listed
Triamcinolone Acetonide 1 mg/g 72162-2336-02 Bryant 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 67296-1927-01 RedpharmDrug 1 tube AT FDA listed
Triamcinolone acetonide 1 mg/g 68071-2362-05 NuCare 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 68788-8386-05 Preferred 1 tube AT FDA listed
Triamcinolone Acetonide 1 mg/g 85766-0244-15 Sportpharm 1 tube AT FDA listed
Triamcinolone acetonide 1 mg/g 67296-2327-01 Redpharm 1 tube AT FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1997
On the market since
Nov 1997
📍
2026
Currently FDA-listed
29 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Triamcinolone Acetonide — the ingredient across all brands.

Top reported reactions

Pruritus2,650
Rash2,534
Pain2,232
Fatigue2,133
Nausea2,043
Headache1,916
Condition Aggravated1,747

Reporter sex

31,697 reports
Male · 34%
Female · 66%
Unknown · 0%

Serious outcomes

Hospitalization6,577
Death3,076
Disabling2,415
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 4,201 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
68071-2736-03 You're viewing this 1 TUBE in 1 CARTON (68071-2736-3) / 30 g in 1 TUBE 2022-05-26 Active

🧭 About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 68071-2736-3, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 68071-2736-03, written without dashes as 68071273603. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 68071-2736-03, the first segment (68071) is the labeler code FDA assigned to NuCare Pharmaceuticals,Inc.; the middle segment (2736) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (03) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by NuCare Pharmaceuticals,Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
NuCare Pharmaceuticals,Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 21 words

INDICATIONS AND USAGE Triamcinolone acetonide cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 191 words

DOSAGE AND ADMINISTRATION Apply triamcinolone acetonide cream USP, 0.1% as appropriate, to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions.

Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication.

The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply triamcinolone acetonide cream USP, 0.1% under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day.

Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications 21 words

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

🤒 Adverse Reactions 59 words

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

🤰 Pregnancy 94 words

Pregnancy Teratogenic Effects Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 113 words

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 18 words

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General ).

🧬 Clinical Pharmacology 192 words

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 26 words

HOW SUPPLIED Triamcinolone Acetonide Cream USP, 0.1% in 30 g (NDC 6871-2736-3) tubes. Store at controlled room temperature 20° to 25°C (68° to 77°F). Avoid freezing.

📦 Storage and Handling 13 words

Store at controlled room temperature 20° to 25°C (68° to 77°F). Avoid freezing.

📋 Description 75 words

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone acetonide is designated chemically as 9-Fluoro-11β, 16α, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone.

Each gram of 0.1% triamcinolone acetonide cream provides 1 mg triamcinolone acetonide, respectively, in a vanishing cream base containing cetyl alcohol, cetyl esters wax, glyceryl monostearate, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water. Chemical Structure

💬 Information for Patients 122 words

Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for dermatologic use only. Avoid contact with the eyes.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. Patients should report any signs of local adverse reactions especially under occlusive dressing.

Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.